Company profile
Ticker
RXRX
Exchange
Website
CEO
Dr. Christopher C. Gibson Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • Acorda Therapeutics • Saratoga Investment ...
Former names
Recursion Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Exscientia Limited • Exscientia (UK) Holdings Ltd. • Exscientia AI Ltd. • Kinetic Discovery Ltd • Exscientia Inc. • Exscientia Ventures I Inc. • RE Ventures I LLC • Exscientia Ventures II Inc. • RE Ventures II LLC • Exscientia GmbH ...
IRS number
464099738
RXRX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
28 Feb 25
10-K
2024 FY
Annual report
28 Feb 25
8-K
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
28 Feb 25
S-3ASR
Automatic shelf registration
12 Feb 25
8-K
Decoding Biology to Radically Improve Lives JANUARY 2025
13 Jan 25
8-K
Other Events
17 Dec 24
424B7
Prospectus with selling stockholder info
17 Dec 24
8-K
Departure of Directors or Certain Officers
3 Dec 24
8-K/A
Financial Statements and Exhibits
27 Nov 24
8-K/A
Unregistered Sales of Equity Securities
26 Nov 24
Latest ownership filings
4
Christopher Gibson
7 Mar 25
144
Notice of proposed sale of securities
6 Mar 25
144
Notice of proposed sale of securities
5 Mar 25
4
Christopher Gibson
20 Feb 25
4
Ben R Taylor
20 Feb 25
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 25
SC 13G/A
ARK Investment Management LLC
14 Feb 25
SC 13G/A
BAILLIE GIFFORD & CO
12 Feb 25
4
Christopher Gibson
7 Feb 25
144
Notice of proposed sale of securities
6 Feb 25
Financial summary
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 603.02 mm | 603.02 mm | 603.02 mm | 603.02 mm | 603.02 mm | 603.02 mm |
Cash burn (monthly) | (no burn) | (no burn) | 61.26 mm | 39.92 mm | 38.48 mm | 29.93 mm |
Cash used (since last report) | n/a | n/a | 138.17 mm | 90.04 mm | 86.79 mm | 67.51 mm |
Cash remaining | n/a | n/a | 464.86 mm | 512.99 mm | 516.24 mm | 535.51 mm |
Runway (months of cash) | n/a | n/a | 7.6 | 12.9 | 13.4 | 17.9 |
Institutional ownership, Q4 2024
80.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 316 |
Opened positions | 86 |
Closed positions | 38 |
Increased positions | 114 |
Reduced positions | 59 |
13F shares | Current |
---|---|
Total value | 2.04 tn |
Total shares | 316.61 mm |
Total puts | 3.64 mm |
Total calls | 2.82 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 34.01 mm | $229.91 bn |
ARK Investment Management | 32.35 mm | $218.66 bn |
Baillie Gifford & Co | 24.86 mm | $168.08 bn |
BlackRock | 23.44 mm | $158.43 bn |
SFTBY SoftBank | 14.67 mm | $99.15 bn |
Mubadala Investment Co PJSC | 12.99 mm | $87.78 bn |
STT State Street | 12.58 mm | $85.03 bn |
Kinnevik AB (publ) | 11.91 mm | $80.48 bn |
Novo Holdings A/S | 10.11 mm | $68.37 bn |
MIC Capital Management UK | 9.64 mm | $65.19 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 25 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 6.37 | 20,000 | 127.40 k | 1,256,024 |
6 Mar 25 | Christopher Gibson | Class A Common Stock | Conversion | Acquire C | No | No | 0 | 20,000 | 0.00 | 1,276,024 |
6 Mar 25 | Christopher Gibson | Class B Common Stock Class A Common Stock | Conversion | Dispose C | No | No | 0 | 20,000 | 0.00 | 5,896,700 |
5 Mar 25 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 6.58 | 20,000 | 131.60 k | 1,256,024 |
5 Mar 25 | Christopher Gibson | Class A Common Stock | Conversion | Acquire C | No | No | 0 | 20,000 | 0.00 | 1,276,024 |
5 Mar 25 | Christopher Gibson | Class B Common Stock Class A Common Stock | Conversion | Dispose C | No | No | 0 | 20,000 | 0.00 | 5,916,700 |
18 Feb 25 | Christopher Gibson | Class A Common Stock | Payment of exercise | Dispose F | No | No | 10.64 | 17,132 | 182.28 k | 1,256,024 |
18 Feb 25 | Taylor Ben R | Class A Common Stock | Payment of exercise | Dispose F | No | No | 10.64 | 10,879 | 115.75 k | 875,727 |
6 Feb 25 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 8.12 | 20,000 | 162.40 k | 1,273,156 |
6 Feb 25 | Christopher Gibson | Class A Common Stock | Conversion | Acquire C | No | No | 0 | 20,000 | 0.00 | 1,293,156 |
News
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
2h ago
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
4d ago
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
1w ago
Leerink Partners Maintains Market Perform on Recursion Pharmaceuticals, Lowers Price Target to $6
1w ago
Recursion Pharmaceuticals Q4 EPS $(0.53) Misses $(0.46) Estimate, Sales $4.55M Miss $19.04M Estimate
1w ago
Press releases
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
1w ago
Altitude Lab Startups Raise $154M in Capital
2w ago
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
1mo ago
Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028
1mo ago
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
1mo ago